Historical mrk News Stories
Merck Q3 Beats; Verona Deal, Guidance Trim Ahead!!
Merck delivered a strong Q3 led by Keytruda and Winrevair, closed the Verona Pharma acquisition for Ohtuvayre, and tightened full‑year revenue guidance — a mix that drove stock reaction even as pipeline approvals and manufacturing investments support longer‑term growth.
Merck Stretches into Obesity; Cuts Oncology Bets Now
Merck (MRK) this week struck a licensing deal to enter obesity therapeutics, paused several late‑stage oncology programs, and gained regulatory momentum in other areas. The Hansoh partnership for preclinical GLP‑1 candidate HS‑10535, EMA's favorable opinion for Welireg, and an RSV prophylactic filing highlight a strategic refocus that could reshape near‑term expectations for MRK stock.